Company / Operating Cash Flow
Harmony Biosciences Holdings, Inc. Operating Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$348.2M
FY2025
5-year range
-$75.4M / $348.2M
FY2021-FY2025
Trend
+58.4%
vs FY2024
Sector context
#31 of 216
Health Care
What the data says
Harmony Biosciences Holdings, Inc.'s operating cash flow of $348M is higher than 86% of companies in the Health Care sector (FY2025). Operating Cash Flow has increased for 4 consecutive years, from -$75M in FY2021 to $348M in FY2025.
Based on SEC 10-K filings.
$348M in FY2025 with a 3-year CAGR of +34.1%. Top quartile in the Health Care sector.
Improved from $219M to $348M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +34.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-47.2% below sector average
Key checks
Key Insights
- Harmony Biosciences Holdings, Inc.'s operating cash flow has grown for 4 consecutive years.
- 3-year CAGR of +34.1%, indicating consistent growth.
- In FY2025, operating cash flow increased 58.4% year-over-year.
- Ranks #31 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $348.2M | +58.4% |
| FY2024 | $219.8M | +0.2% |
| FY2023 | $219.4M | +51.9% |
| FY2022 | $144.5M | +291.5% |
| FY2021 | -$75.4M | +0.0% |
| FY2020 | -$75.4M | +0.0% |
| FY2019 | -$75.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026